ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2119

Rheumatological Immune Related Adverse Events in Malignancy Patients Treated with Anti-Programmed Cell Death (PD) 1 Antibodies

Emma Mitchell1, Peter Lau2, Chloe Khoo2, Kortnye Smith2, Benjamin Brady2, Mark Shackleton2, Grant McArthur2, Ian Wicks1,3,4 and Shahneen Sandhu2, 1Rheumatology, Royal Melbourne Hospital, Melbourne, Australia, 2Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia, 3Medicine, University of Melbourne, Melbourne, Australia, 4Wicks Lab, Walter and Eliza Hall Institute, Melbourne, Australia

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Adverse events, cancer treatments and rheumatologic disease, Immunotherapy

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 7, 2017

Session Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Immune checkpoint inhibitors (ICIs), including anti-programmed cell death 1 (anti-PD 1) antibodies, are established therapies for advanced malignancies, including melanoma, and non-small cell lung cancer (NSCLC). The adverse event (AE) profile of anti-PD 1 antibodies includes immune-related adverse events (irAEs) spanning several organ systems, many of which have defined management pathways. However, no consensus exists for the management of rheumatological (Rh) irAEs, including inflammatory arthritis, PMR and myositis, which affect 5-10% of patients receiving anti-PD 1 antibodies. Equally, there is a paucity of data presenting management options for flares of pre-existing rheumatic disease whilst undertaking anti-PD 1 therapy.

Methods:

We conducted a single centre retrospective study of patients treated with anti-PD 1 antibodies pembrolizumab (P) and nivolumab (N), who developed Rh irAEs, experienced flares of existing rheumatic disease, or experienced stability of existing rheumatic disease. Clinical and demographic data were obtained, including anti-PD 1 response (timing, durability and reason for cessation), rheumatologic presentation (including temporal relationship to anti-PD 1 therapy), rheumatologic treatment and response.

Results:

Eighteen patients (12 male, 6 female; median age 71.5 years) were included. All had metastatic malignancy (14 melanoma, 2 NSCLC, 2 head and neck squamous cell carcinoma). Anti-PD1 monotherapy (P or N) was used in 17 patients, 1 of whom had previously received the anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4) antibody ipilimumab (I). One patient received combination N-I.

Thirteen patients developed de novo Rh irAEs (7 inflammatory arthritis, 1 PMR, 4 myositis, 1 fasciitis). Three experienced flare of Rh disease (all PMR). Two patients had no flare of their existing Rh disease (1 PMR, 1 with JIA/SSc). The median time to Rh irAE was 10.9 weeks (range 0.7-113). All myositis cases manifested within 4 weeks.

Twelve of the 16 irAEs required prednisone, all at doses ≥10mg/day. DMARDs were used in 5 cases, including HCQ in 4, MTX in 1, and SSZ in 1. One case received intravenous immunoglobulin.

Of the 18 patients, 7 completely responded to anti-PD 1, 7 partially responded, 3 had stable disease, and 1 progressive disease. Responses have been maintained despite Rheumatologic therapy. Median duration of response has not been reached.

Conclusion:

Rh irAEs to anti-PD 1 therapy present a new challenge for Rheumatologists and Oncologists. Both de novo disease, and flare, can occur. Our cohort demonstrated a high rate of response to anti-PD 1 therapy, including when Rheumatologic therapy was initiated. Prospective analysis is required to further characterise this set of diseases.


Disclosure: E. Mitchell, None; P. Lau, None; C. Khoo, None; K. Smith, None; B. Brady, None; M. Shackleton, None; G. McArthur, None; I. Wicks, None; S. Sandhu, None.

To cite this abstract in AMA style:

Mitchell E, Lau P, Khoo C, Smith K, Brady B, Shackleton M, McArthur G, Wicks I, Sandhu S. Rheumatological Immune Related Adverse Events in Malignancy Patients Treated with Anti-Programmed Cell Death (PD) 1 Antibodies [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/rheumatological-immune-related-adverse-events-in-malignancy-patients-treated-with-anti-programmed-cell-death-pd-1-antibodies/. Accessed April 11, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatological-immune-related-adverse-events-in-malignancy-patients-treated-with-anti-programmed-cell-death-pd-1-antibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.